| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $889,610 ) |
| | 2025 | 2025 | TAXIS PHARMACEUTICALS INC | 9 DEERPARK DR STE J15 | MONMOUTH JUNCTION | NJ | 08852-1979 | MIDDLESEX | USA | R44AI174351 | Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa | 000 | 2 | NIH | 3/25/2025 | $889,610 |
|
| Issue Date FY: 2024 ( Subtotal = $910,179 ) |
| | 2024 | 2024 | TAXIS PHARMACEUTICALS INC | 9 DEERPARK DR STE J15 | MONMOUTH JUNCTION | NJ | 08852-1979 | MIDDLESEX | USA | R44AI174351 | Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa | 000 | 1 | NIH | 4/26/2024 | $910,179 |
|
|
